1. Haranaka K. Tumor necrosis factor: how to improve the anti-tumor activity and decrease accompanying side effects for therapeutic application. J Biol Response Modif 1988; 7: 525–34.
2. Zimmerman RJ, Marafino BJ, Chan A, Landre P, Winkelhake JL. The role of oxidant injury in tumor cell sensitivity to recombinant human tumor necrosis factorin vivo. J Immunol 1989; 142: 1405–9.
3. Zimmerman RJ, Chan A, Leadon SA. Oxidative damage in murine tumor cells treatedin vitro by recombinant human tumor necrosis factor. Cancer Res 1989; 49: 1644–8.
4. Haranaka K, Satomi N. Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cellsin vitro. Jpn J Exp Med 1981; 51: 191–4.
5. Sato N, Sawasaki Y, Haranaka K, Satomi N, Nariuchi H, Goto T. Growth inhibitory and cytotoxic action of rabbit tumor necrosis factor against bovine capillary endothelial cellsin vitro. Proc Japan Acad 1985; 61B: 471–4.